Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference

    <<



    >>

Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the 13th Annual Biotech and Specialty Pharmaceuticals Conference, sponsored by the New York Society of Securities Analysts, at 2:05 on December 1, 2009. The conference is being held at the offices of the New York Society of Security Analysts, 1177 Avenue of the Americas, New York, NY.

For further information about this conference, please contact Derly Vargas at 646-871-3405 or dvargas@nyssa.org.

    <<

    About Echo Therapeutics

    >>

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

    <<

    Cautionary Statement Regarding Forward Looking Statements

    >>

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

10 Forge Parkway Franklin, MA 02038, USA Tel: 1+ 877-476-6878 Fax: 1+ 508-553-8760 www.echotx.com

    <<



    © 2002 - 2009 Echo Therapeutics, Inc. All rights reserved worldwide.


    >>

For More Information: Patrick T. Mooney, M.D. Chairman and Chief Executive Officer (508)-530-0329

    <<








    >>

SOURCE: Echo Therapeutics, Inc.

Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics,
Inc., +1-508-530-0329 Web Site: http://www.echotx.com

Related terms: annual report, ceo, commercial, conference, debt, diabetes, equity, fda, hospital, market, marketing, massachusetts, medical, new york, otc, pharmaceuticals, products, research, sec-8k, securities, security, technology, wireless